Abstract
Arsenic trioxide (As2O3; ATO), a compound which is characterized by its ability to function as a potent anticancer agent, has been investigated in a variety of carcinomas. B7‑H4, a transmembrane protein, may inhibit the function of the T cell effector, and therefore, may be useful in investigating different types of tumor therapies. However, few studies have been published previously associated with the roles of ATO and B7‑H4 in human hepatocellular carcinoma (HCC). The aim of the present study was to investigate the anti‑invasive role of ATO in HCC, to determine the effect of ATO treatment on the expression of B7‑H4 and to further assess the possible underlying mechanisms. Following treatment of the cells with 2, 4 and 8 µM ATO for 48 h, cell counting kit‑8 (CCK‑8), Transwell and western blot assays were used to determine the extent of human MHCC97‑H HCC cell proliferation, apoptosis, invasion and B7‑H4 expression, respectively. The results revealed that 1 µM ATO markedly decreased cellular proliferation, and ATO administered at concentrations of 0.1, 0.2 and 0.5 µM markedly inhibited the migration and invasion of the human MHCC97‑H HCC cell line. The expression of B7‑H4 in the treatment groups was markedly reduced. Signal tra...Continue Reading
References
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Jun 20, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yuping SunXiongbiao Wang
Jun 27, 2006·Proceedings of the National Academy of Sciences of the United States of America·Amy E KrambeckEugene D Kwon
Dec 4, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Lei ChengBeihua Kong
Apr 7, 2010·Cancer Genetics and Cytogenetics·De-Dong WuJie Hou
Nov 30, 2010·Journal of Medical Case Reports·Yoshito TomimaruShingi Imaoka
May 23, 2012·The Journal of International Medical Research·S-Q SunP-L Huang
Jul 19, 2012·Oncology Letters·Byung Soh MinHyun Cheol Chung
Mar 8, 2013·Clinical and Experimental Medicine·Eun-Young KimSeung Yon Baek
Mar 27, 2013·Metallomics : Integrated Biometal Science·Pei LiuZhe Chen
May 11, 2013·Cell and Tissue Research·Yun QianLihuang Zhang
May 21, 2013·Journal of Autoimmunity·Joseph R PodojilStephen D Miller
Jun 19, 2013·Journal of Reproductive Immunology·Dorota Darmochwal-KolarzJan Oleszczuk
Jul 3, 2013·Cell Biochemistry and Biophysics·Sandra RadenkovicKristina Gopcevic
Jul 12, 2013·Immunopharmacology and Immunotoxicology·Nanna N KristensenMogens H Claesson
Jul 16, 2013·Macromolecular Bioscience·Hailong HuangJingyuan Wang
Aug 27, 2013·Immunology Letters·Lujun ChenJingting Jiang
Oct 2, 2013·Oncoimmunology·Denarda Dangaj, Nathalie Scholler
Oct 12, 2013·World Journal of Gastroenterology : WJG·Jung Woo Shin, Young-Hwa Chung
Mar 22, 2014·Molecular and Clinical Oncology·Wenting LiuFumitaka Kikkawa
Apr 8, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Jing WangYaguang Weng
May 21, 2014·Cancer Research·Lola RahibLynn M Matrisian
Jun 3, 2014·Journal of Experimental & Clinical Cancer Research : CR·Sanjay KumarPaul B Tchounwou
Jun 7, 2014·Ecotoxicology and Environmental Safety·Shuvasree SarkarShelley Bhattacharya
Jul 1, 2014·Cancer·Andrew J PageTimothy M Pawlik
Jul 1, 2014·Journal of the Turkish German Gynecological Association·Nafiye YılmazFeride İffet Sahin
Citations
Nov 19, 2019·Current Cancer Drug Targets·Md WahiduzzamanYoshitaka Hosokawa
Dec 10, 2020·Expert Opinion on Drug Delivery·Vikas KumarHyung Sik Kim
Nov 18, 2019·Cellular Immunology·Jia-Yu Wang, Wei-Peng Wang
Feb 3, 2018·Oncology Research·Haoran WuZhong Lü